TissueGnostics is an industrial beneficiary of eRaDicate consortium
18. March 2024
The eRaDicate consortium consists of eight academic and one industrial beneficiaries, as well as 13 associated partners to develop new therapies against cancer stem cell-driven relapse and metastasis.